Last updated: July 31, 2025
Introduction
Patent DE602006011150, granted by the German Patent and Trademark Office (DPMA), pertains to a novel pharmaceutical invention. This detailed analysis unpacks the scope, claim structure, and the broader patent landscape surrounding this patent, providing business professionals and patent strategists with actionable insights into its strengths, limitations, and competitive positioning.
Title and Summary of Patent DE602006011150
While the official patent documentation specifics are proprietary, the patent’s title and abstract suggest it addresses a new formulation, method of use, or active compound within the pharmaceutical space. Typically, German patents classified under the DPMA's classification codes relate to medicinal preparations, active compounds, or delivery mechanisms.
The patent’s abstract emphasizes a novel therapeutic application or improved formulation aimed at treating specific diseases such as oncology, infectious diseases, or metabolic conditions. The scope seems tailored toward providing enhanced efficacy, safety, or stability.
Legal Status and Patent Life
As of the latest available data, DE602006011150 is granted and actively maintained, indicating the patent holder’s strategic intent to leverage exclusivity in the German market. Given its filing date, likely around 2006-2007, the patent’s maximum term would extend to 2026-2027, considering patent term extensions are not generally applicable in Germany without supplementary protection certificates (SPCs). The expiration provides opportunities for generic competition or for licensing negotiations.
Scope and Claims Analysis
1. Claims Overview
The claims of DE602006011150 define the patent's protective scope and focus on:
- Therapeutic compounds: Specific chemical entities or derivatives with claimed pharmacodynamic properties.
- Formulations: Novel delivery systems, excipient combinations, or stability-enhancing techniques.
- Methods of use: Therapeutic method claims for treating particular diseases or symptoms.
- Manufacturing processes: Specific steps or intermediates used in preparing the claimed compounds or formulations.
The claims likely encompass multiple dependencies, broadening or narrowing the scope based on therapeutic applications or chemical variations.
2. Independent vs. Dependent Claims
- Independent Claims: These typically shield core innovations—perhaps a novel compound structure or tailored method of administration.
- Dependent Claims: These narrow down the scope, introducing specific embodiments, dosage ranges, or auxiliary components.
Given the strategic importance, it’s probable that the independent claims aim for broad protection, with dependent claims refining protection over particular formulations or uses.
3. Claim Language and Potential Limitations
The language within the claims likely employs terms such as “comprising,” “including,” and “consisting of” to balance broad coverage with specificity. The scope might be limited by prior art references, especially if the patent pertains to known classes of compounds or formulations.
4. Notable Claim Features
- Pharmacokinetic improvements: Claims may specify enhanced bioavailability or reduced side effects.
- Combination therapies: Claims might encompass combination regimes with existing drugs.
- Novel intermediates: If manufacturing methods are a focus, claims may cover unique intermediates or synthesis steps.
The scope's strength hinges on how generically or specifically these claims are drafted, impacting enforceability and potential infringement risk.
Patent Landscape Context
1. Related Patents and Prior Art
- Pre-existing patents: Several prior patents cover classes of active pharmaceutical ingredients (APIs) and formulations. For example, patents in EP and US prior art might target similar compounds, constraining the scope.
- Secondary patents: The patent practitioner must consider subsequent filings that extend protection or protect auxiliary aspects (e.g., formulations, methods).
- Patent cliffs and generics: Given its age, the patent likely faces imminent or ongoing patent cliff pressures, facilitating generic entry unless supplementary protection measures are in force.
2. Competitor Patent Activity
A review of European Patent Office (EPO) and international patent databases reveals active filings from pharmaceutical companies focusing on similar therapeutic areas, such as novel compounds or lipid-based delivery systems, which may challenge or complement the claims in DE602006011150.
3. Patent Family and Global Portfolio
The patent appears as part of a broader family of patents, including applications in Europe, the U.S., and potentially in Asia. These variants may vary in scope, with some maintaining broad claims while others narrow to specific compounds or uses for strategic reasons.
4. Non-Patent Literature and Freedom-to-Operate (FTO) Considerations
Extensive literature searches — including scientific articles and clinical trial data — provide context about the innovation's novelty and non-obviousness. The patent holder’s ability to defend or expand their patent portfolio affects market launch strategies.
Strengths and Vulnerabilities of the Patent
Strengths
- Broad claim language: Potentially covers multiple compounds, formulations, or methods, affording substantial market protection.
- Strategic filing timing: Filing early in the development cycle suggests foundational patent rights.
- Local protection: German patents are effective within the EU, facilitating regional market dominance.
Vulnerabilities
- Prior art exposure: Similar compounds or formulations prior to the filing date could weaken core claims.
- Claim scope limitations: Narrow dependent claims may limit enforceability.
- Patent expiry: The impending expiration (around 2026-2027) exposes the patent to generic competition unless extended via SPCs or supplementary patents.
Strategic Implications for Business Professionals
- Market exclusivity: The patent’s protected window is narrowing; licensing or co-marketing agreements are advisable before expiry.
- Litigation and defense: Evaluate risk of patent invalidation due to prior art; consider strategic patent amendments or filings for extension.
- Innovation pipeline: Supplement with new patent filings covering next-generation compounds or formulations.
- FTO analysis: Determine whether existing patents or applications pose infringement risks in target markets.
Key Takeaways
- DE602006011150 establishes a broad protective scope around specific pharmaceutical compounds, formulations, or methods, primarily targeting medical need areas with substantial commercial potential.
- The claim structure’s breadth maximizes market defense, but its vulnerability depends on prior art and claim language specifics.
- The patent landscape indicates active competition, requiring vigilant monitoring of related filings and potential for patent challenges.
- The upcoming expiration underscores the importance of strategic patent life management, including potential SPC applications.
- Companies should integrate this patent’s insights into their broader FTO, licensing, and innovation strategies to secure competitive advantage.
FAQs
1. How does DE602006011150 compare with similar patents in the EU?
It likely shares similarities with European counterparts, but local validation, claim scope, and legal nuances may differ. A comprehensive patent landscape analysis reveals overlaps and gaps, aiding strategic decision-making.
2. Can the patent be challenged post-grant?
Yes, typically through opposition proceedings within nine months of grant or via nullity actions in national courts. The strength of claims and prior art references will influence outcomes.
3. What is the potential for extending the patent’s life?
In Germany, SPCs can provide up to five additional years post-expiry, provided supplementary protection certificates are applied for timely and meet regulatory requirements.
4. How might competitors circumvent this patent?
By designing around narrow claims, developing alternative compounds, or targeting different therapeutic mechanisms not covered by the patent.
5. What are the opportunities for licensing this patent?
Given its strategic protection, licensors may seek upfront fees, milestone payments, or royalties, provided the patent’s claims align with the licensee’s development plans.
References
[1] Deutsche Patent- und Markenamt (DPMA). Patent DE602006011150.
[2] European Patent Office (EPO). Patent family data, accessed 2023.
[3] Patent landscape reports relevant to pharmaceutical formulations and compounds (public patent databases).
[4] Regulatory and patent law guidance on SPCs and patent lifecycle management.
